BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 11, 2007
View Archived Issues
Erbitux Misses In Pancreatic Cancer, Dropping ImClone
Shares in ImClone Systems Inc. took a 6.4 percent dip on word that Erbitux (cetuximab) missed the primary endpoint in a Phase III pancreatic cancer study, a backslide that follows a month of significant gains. (BioWorld Today)
Read More
Ascenta Raises $50M For Apoptosis Phase II Trials
Read More
Entereg Data Show Heart Risks, Adolor Plummets
Read More
Inhibitex Acquiring FermaVir In All-Stock Deal Valued At $19M
Read More
Biosite To Consider IMI's Offer Over Rival Beckman
Read More
Advancis Raising $24M To Get Amoxicillin Pulsys To Market
Read More
Other News To Note
Read More
Clinic Roundup
Read More